It encapsulated Fe3O4 NPs and TLR7 agonist imiquimod (R837), which could synergistically repolarize TAMs from M2 to antitumor M1 phenotype.1086 Resiquimod, also known as R848, is a TLR7/8 agonist shown to enhance cancer immunotherapy by promoting the transformation of M2 macrophages into M1.1087,1088 In vitro studies have shown that cathepsin B (CTSB)-responsive programmed brain-targeted delivery system (D&R-HM-MCA) could go through the BBB of glioblastoma (GBM) with high endocytosis efficiency and promote the repolarization of M2 macrophages into M1 type by the delivery of resiquimod.1089. Here, TLR7 is linked to cancer.